SANTA CRUZ BIOTECHNOLOGY, INC.

KRTAP22-2 siRNA (m): sc-108173

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

The smallest of the human chromosomes, 21, makes up about 1.5% of the human genome. Chromosome 21 contains nearly 300 genes and 47 million base pairs. Down syndrome, also known as trisomy 21, is the disease most commonly associated with chromosome 21. Alzheimer's disease, Jervell and Lange-Nielsen syndrome and amyotrophic lateral sclerosis are also associated with chromosome 21. Translocations are found to occur between chromosome 21 and 8, and chromosome 21 and 12 in certain leukemias.

REFERENCES

1. Tesson, F., Donger, C., Denjoy, I., Berthet, M., Bennaceur, M., Petit, C., Coumel, P., Schwarts, K. and Guicheney, P. 1996. Exclusion of KCNE1 (IsK) as a candidate gene for Jervell and Lange-Nielsen syndrome. J. Mol. Cell. Cardiol. 28: 2051-2055.
2. Tyson, J., Tranebjaerg, L., Bellman, S., Wren, C., Taylor, J.F., Bathen, J., Aslaksen, B., Sorland, S.J., Lund, O., Malcolm, S., Pembrey, M., Bhattacharya, S. and Bitner-Glindzicz, M. 1997. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum. Mol. Genet. 6: 2179-2185.
3. Müller, S., Stanyon, R., Finelli, P., Archidiacono, N. and Wienberg, J. 2000. Molecular cytogenetic dissection of human chromosomes 3 and 21 evolution. Proc. Natl. Acad. Sci. USA 97: 206-211.
4. Mao, R., Wang, X., Spitznagel, E.L., Jr., Frelin, L.P., Ting, J.C., Ding, H., Kim, J.W., Ruczinski, I., Downey, T.J. and Pevsner, J. 2005. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol. 6: R107.
5. Robakis, N.K. 2006. The discovery and mapping to chromosome 21 of the Alzheimer's amyloid gene: history revised. J. Alzheimers Dis. 10: 453-455.
6. Sun, X., He, G. and Song, W. 2006. BACE2, as a novel APP θ-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. 20: 1369-1376.
7. Aït Yahya-Graison, E., Aubert, J., Dauphinot, L., Rivals, I., Prieur, M., Golfier, G., Rossier, J., Personnaz, L., Creau, N., Bléhaut, H., Robin, S., Delabar, J.M. and Potier, M.C. 2007. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet. 81: 475-491.
8. Peterson, L.F., Boyapati, A., Ahn, E.Y., Biggs, J.R., Okumura, A.J., Lo, M.C., Yan, M. and Zhang, D.E. 2007. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 110: 799-805.
9. Ryoo, S.R., Jeong, H.K., Radnaabazar, C., Yoo, J.J., Cho, H.J., Lee, H.W., Kim, I.S., Cheon, Y.H., Ahn, Y.S., Chung, S.H. and Song, W.J. 2007. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem. 282: 34850-34857.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: Krtap22-2 (mouse) mapping to 16 C3.3.

PRODUCT

KRTAP22-2 siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see KRTAP22-2 shRNA Plasmid (m): sc-108173-SH and KRTAP22-2 shRNA (m) Lentiviral Particles: sc-108173-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 µl of RNAse-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

KRTAP22-2 siRNA (m) is recommended for the inhibition of KRTAP22-2 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RESEARCH USE

For research use only, not for use in diagnostic procedures.